NCT03984916

Study of the Bioavailability of Three Hesperidin Extracts.

Interventional Study for the Comparison of the Bioavailability of Three Hesperidin Extracts (HESPERIDIN).

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Technological Centre of Nutrition and Health, Spain · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The flavonoid hesperidin is present abundantly in citrus fruits and citrus juices. The results of numerous studies suggest that hesperidin perform several beneficial effects on health, including antitumor, antioxidant, anti-inflammatory, hypocholesterolemic and hypoglycemic effects as well as decreasing blood pressure. There are two isomers of hesperidin, -S and -R, being the predominant form in nature the isomer -S. However, currently commercialized hesperidin consists of a mixture of both isomers due to the extraction process of the hesperidin from natural sources. The presence of the rutin disaccharide conjugated to the hesperidin molecule is responsible that most of the ingested hesperidin is metabolized by bacteria in the colon through the enzymatic activity α-rhamnosidase, being this enzymatic activity the limiting step of the hydrolysis and absorption of hesperidin. It has been suggested that the low levels of this enzymatic activity in the gut microbiota is the cause of the low bioavailability of hesperidin and also, at least in part , of the high interindividual variability that exists in the absorption of this compound. The micronization process in order to decrease the size of the hesperidin particles is presented as a way to increase the bioavailability of hesperidin. Another way to increase the absorption of hesperidin that is proposed in this study is to increase the proportion of the isomer -S in the extracts of hesperidin, since being the isomer that mostly occurs in nature, the gut microbiota will have a greater capacity of metabolism for this isomer. On this basis the present hypothesis is posed: the administration of hesperidin formed mainly by the isomer -S and micronized, will present greater bioavailability than hesperidin formed by a mixture of the isomers -S and -R. In turn, the bioavailability of the hesperidin formed mainly by the isomer -S and micronized will present greater bioavailability than the mixture of the isomers -S and -R and micronized. The main objective of this study was to quantify the bioavailability of three extracts of hesperidin: * Hesperidin extract with a mixture of the isomers -S and -R. * Hesperidin extract with a mixture of the isomers -S and -R micronized. * Hesperidin extract with the isomer -S micronized.

Detailed description

It will be conducted a post-prandial, randomized, crossover, and double-blind nutritional intervention study. In a first phase, it will be done a pre-selection process with 30 male and female volunteers over 18 years of age. It will be determined hesperidin excreted levels in urine after the consumption of 500 mL of a homogeneous orange juice among all the participants. Sixteen participants will be selected preferably with an intermediate capacity of hesperidin absorption. The aim of this first phase is to obtain a lower variability in the results in the second phase of the study. Of the sixteen participants, six participants will start the study with the consumption of a hesperidin extract, five with the consumption of the second hesperidin extract and five with the consumption of the third hesperidin extract for, after one week washing period, exchange the hesperidin extracts between the three study groups, and finally repeat the exchange of hesperidin extracts after another week of washing period so that, in the total of the study, each participant had consumed the three hesperidin extracts. Participants will consume two capsules with 250 mg of extract each, being the total orange extract consumed 500 mg, with 450 mg of hesperidin (90%) and the rest (10%) substances coming from the orange in the process of extracting hesperidin. During the study there will be 5 visits, one selection (V0), one pre-inclusion (V-1) and 3 study visits (V1, V2 and V3).

Conditions

• Biological Availability

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Hesperidin Pharma	Two capsules with 250 mg of sweet orange extract with a mixture of hesperidin isomers -S and -R.
DIETARY_SUPPLEMENT	Hesperidin Pharma_M	Two capsules with 250 mg of sweet orange extract each with a mixture of hesperidin isomers -S and -R and micronized.
DIETARY_SUPPLEMENT	Cardiose	Two capsules with 250 mg of sweet orange extract each with more than 90% of hesperidin as isomer -S and micronized.

Timeline

• Start date: 2019-06-13
• Primary completion: 2020-03-02
• Completion: 2020-03-02
• First posted: 2019-06-13
• Last updated: 2022-02-28

Locations

1 site across 1 country: Spain